(Boursier.com) – As an extension of the press release of November 23, 2021, Biosynex informs the financial community of the final completion on December 29, 2021 of the acquisition of the human health branch of Enalees, a company specializing in the development and manufacture of rapid molecular diagnostic tests using an isothermal amplification method.
Enalees specializes in veterinary applications and has also collaborated with other manufacturers during the COVID-19 pandemic to develop a test for the detection of SARS-CoV-2 RNA by isothermal amplification, validated with the competition from the Institut Pasteur. This acquisition is strategic for Biosynex because it includes a technology transfer allowing Biosynex to develop and produce at its Strasbourg site diagnostic tests based on the isothermal amplification of the DNA of infectious agents (viruses, bacteria and parasites) can be done piecemeal in about thirty minutes. Biosynex plans to deploy this technology on a wide range of infectious parameters. Development is underway in neonatology. Others will soon be in the field of tropical and respiratory infections. These tests will be primarily intended for use in satellite laboratories with limited equipment or in emergency hospital laboratories.
The acquisition is accompanied by the granting by Enalees to Biosynex of a promise to license the use of a filter extraction system developed by Enalees and which is currently the subject of a patent application in several territories. .
This acquisition was made entirely in cash and will be accompanied by installment payments depending on the progress of the technology transfer.
© 2022 Boursier.com